Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-12-14

Clinical Trial Update: Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo [NA]

View source ↗

Summary

A completed clinical trial evaluating adjunctive once-daily topical nepafenac 0.3% vs placebo for cystoid macular edema, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nepafenac 0.3% (nepafenac)

Snippet

Sponsor: Intuor Technologies, Inc. | Conditions: Cystoid Macular Edema | NA | Status: COMPLETED | Results posted: 2018-12-14